5 January 2026 in Pharmaceutical Sciences
Background: Ferroptosis, an iron-dependent cell death driven by lipid peroxidation, is implicated in the pathogenesis of various organ injuries. As preeclampsia threatens maternal liver health via this pathway, we investigated melatonin’s anti-ferroptotic efficacy in an L-NAME-induced rat model of preeclampsia, focusing on its mechanistic modulation. Methods: Preeclampsia was induced in timed-pregnant Wistar rats via daily subcutaneous injections of L-NAME (125 mg/kg) from gestational day (GD) 13 until delivery. Treatment groups received intraperitoneal melatonin (10 mg/kg/day) in either a short-term (STM; GD14 to delivery) or a long-term (LTM; GD14 to postpartum day 14) regimen. Evaluations were performed at 23 and 90 days postpartum (PPD23 and PPD90). Systolic blood pressure and 24-hour urinary protein excretion were quantified. Hepatic oxidative stress status was evaluated by measuring malondialdehyde (MDA) concentration alongside the activities of superoxide dismutase (SOD) and glutathione peroxidase (GPx). Hepatic gene expression of ferroptosis-related mediators was analyzed, including nuclear factor erythroid 2-related factor 2 (NRF2), solute carrier family 7 member 11 (SLC7A11), sulfiredoxin-1 (SRXN1), and glutathione peroxidase 4 (GPX4). A comprehensive histopathological examination of liver tissue was also performed. Results: Melatonin treatment (STM and LTM) significantly attenuated L-NAME-induced hypertension and proteinuria at all time points (P<0.001). It suppressed hepatic oxidative stress, normalizing MDA levels (LTM at PPD90) and elevating SOD/GPx activities (P<0.01). Mechanistically, melatonin reversed the downregulation of ferroptosis-related genes (NRF2, SLC7A11, GPX4; P<0.001), with STM also upregulating SRXN1 at PPD23. LTM showed superior NRF2/GPX4 induction to STM at PPD90. Both melatonin regimens mitigated L-NAME-induced persistent hepatic damage, including ductular reactions and fibrosis. Conclusion: This study demonstrates that melatonin exerts sustained protection against preeclampsia-induced hepatic injury by suppressing ferroptosis through the NRF2/GPX4/SRXN1 pathway. The treatment attenuated ductular reactions and restored redox balance.
26 June 2023 in Journal of Kerman University of Medical Sciences
Background: Elevated serum levels of osteopontin (OPN) have been associated with cardiovascular disease, diabetic nephropathy, and autoimmune disease activity. The aim of this study was to investigate the relationship between OPN serum levels and renal damage in type 2 diabetes patients. Methods: This analytical cross-sectional study was carried out in Yazd, Iran from April to September 2017. Micro-albuminuria and creatinine (Cr) in 750 patients were measured and 180 included patients were divided into the three groups of 60 subjects based on the level of micro-albuminuria; normal (group A), micro proteinuria (group B) and macro proteinuria (group C). Body weight, height, blood pressure, body mass index (BMI), HbA1c and OPN were assessed. Results: Among 179 patients, 60 of them were normal for proteinuria, 59 patients had micro-proteinuria and 60 ones had macro-proteinuria. The mean age of participants was 58.96 (±11.10) years (range 26-80 years), 90 patients (50.8%) were males and 88 ones (49.2%) were females. The mean OPN levels were significantly higher in group C compared to group B, and in group B compared to group A (P=0.0001). Serum OPN was correlated positively with HbA1c (P: 0.012), Cr (P=0.010) and glomerular filtration rate (GFR) (P=0.002). There was a significant difference in the mean of OPN level among the subgroups with the history of ischemic heart disease (IHD) and HbA1C (P=0.035, and 0.047 respectively). Conclusion: These findings suggest that OPN is involved in chronic disease activity, and there is an independent association between plasma levels of OPN, and nephropathy in diabetic patients.